COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (PKVH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01767259
Recruitment Status : Completed
First Posted : January 14, 2013
Last Update Posted : January 15, 2013
Information provided by (Responsible Party):
Sally Helmy, PhD, CPHQ, Damanhour University

Brief Summary:
This study was conducted to compare the rate and extent of absorption of valsartan and hydrochlorothiazide following oral administration as a fixed dose combination tablet and concomitant administration of the individual drugs under fasting conditions in healthy Egyptian subjects. The study was extended to investigate any potential reaction between VAL and HCT.

Condition or disease Intervention/treatment Phase
Healthy Normotensive Participants Drug: Valsartan/Hydrochlorothiazide Drug: Valsartan Drug: Hydrochlorothiazide Not Applicable

Detailed Description:
This study comprised 2 separate parts, I and II; each was a single-dose, open-label, 4-crossover periods separated by a 2 weeks washout, and 4-Treatments. Part I consisted of Treatments A (VAL 160 mg alone), B (HCT 12.5 mg alone), C (VAL 160 mg + HCT 12.5 mg) and D (VAL / HCT 160 mg/12.5mg) and Part II consisted of Treatments E (VAL 320 mg alone), F (HCT 25 mg alone), G (VAL 320 mg + HCT 25 mg) and H (VAL / HCT 320 mg/25 mg). Blood samples were collected up to 48 hours postdose and plasma was analyzed for VAL and HCT concentrations using HPLC. The pharmacokinetic properties of each drug after co-administration of VAL and HCT were compared with those of each drug administered alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers
Study Start Date : October 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Valsartan 160 mg alone
Valsartan alone
Drug: Valsartan
Valsartan alone

Hydrochlorothiazide 12.5 mg alone
Hydrochlorothiazide alone
Drug: Hydrochlorothiazide
Hydrochlorothiazide alone

Valsartan160 mg + Hydrochlorothiazide12.5 mg
Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
Drug: Valsartan/Hydrochlorothiazide
Co-administration or fixed dose combination
Other Names:
  • Fixed dose combination
  • Pharmacokinetic interaction

Valsartan / Hydrochlorothiazide 160 mg/12.5mg
Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
Drug: Valsartan/Hydrochlorothiazide
Co-administration or fixed dose combination
Other Names:
  • Fixed dose combination
  • Pharmacokinetic interaction

Primary Outcome Measures :
  1. Tolerability [ Time Frame: Participants will be followed for the duration of study, an expected average of 6 weeks. ]
    Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • At least 18 years old and not more than 45 healthy male volunteers
  • Actual weight no more than ± 30% from ideal body weight based on sex, height, and body frame
  • Who had passed all the screening parameters
  • Free of any drug exposure known to interfere with the pharmacokinetics or assay of fexofenadine for at least 10 days prior to the study
  • Who had to be able to communicate effectively with study personnel, be literate, and able to give consent.

Exclusion Criteria:

  • A clinically significant abnormal physical exam, medical history, or laboratory studies
  • If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse rate of > 95 or < 50 beats/min at screening
  • A history of serious intolerance, allergy, or sensitivity to fexofenadine
  • The use of any prescription drug within the previous month or use of any over-the-counter medication (with the exception of acetaminophen) within the past 14 days
  • A history of blood dyscrasias
  • A history of alcohol or drug abuse within the past year
  • Donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study
  • Unable to tolerate vein puncture and multiple blood samplings
  • Any surgical/medical condition that might alter drug absorption, distribution, metabolism, or excretion
  • Cannot follow instructions, in the opinion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01767259

Layout table for location information
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University
Damanhour, Egypt
Sponsors and Collaborators
Damanhour University
Layout table for investigator information
Principal Investigator: Sally Helmy, PhD, CPHQ Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Layout table for additonal information
Responsible Party: Sally Helmy, PhD, CPHQ, Lecturer of Pharmaceutics, Faculty of Pharmacy, Damanhour University Identifier: NCT01767259    
Other Study ID Numbers: PPT1
First Posted: January 14, 2013    Key Record Dates
Last Update Posted: January 15, 2013
Last Verified: January 2013
Keywords provided by Sally Helmy, PhD, CPHQ, Damanhour University:
Fixed dose combination
Additional relevant MeSH terms:
Layout table for MeSH terms
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators